Aldeyra Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Aldeyra Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.02%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.02%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ALDX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ALDX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Aldeyra Therapeutics Piyasaya Karşı Temettü Getirisi

ALDX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ALDX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (ALDX) (3 yıla kadar)	0%

Önemli Temettü: ALDX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ALDX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ALDX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ALDX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Aldeyra Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New minor risk - Profitability

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Insider recently bought US$1.1m worth of stock

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aldeyra Therapeutics, Inc. Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial

Aldeyra says trial for dry eye disease candidate reached key goals